Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 590

1.

The economics of effective AIDS treatment in Thailand.

Over M, Revenga A, Masaki E, Peerapatanapokin W, Gold J, Tangcharoensathien V, Thanprasertsuk S.

AIDS. 2007 Jul;21 Suppl 4:S105-16.

PMID:
17620745
2.

Trends and economic stress: a challenge to universal access to antiretroviral treatment in India.

Dhamija P, Bansal D, Medhi B.

Curr HIV Res. 2009 Jul;7(4):410-7.

PMID:
19601776
3.

The costs and benefits of private sector provision of treatment to HIV-infected employees in Kampala, Uganda.

Marseille E, Saba J, Muyingo S, Kahn JG.

AIDS. 2006 Apr 4;20(6):907-14.

PMID:
16549976
4.

Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.

Vijayaraghavan A, Efrusy MB, Mazonson PD, Ebrahim O, Sanne IM, Santas CC.

J Acquir Immune Defic Syndr. 2007 Sep 1;46(1):91-100.

PMID:
17621241
5.

Costs of medical services for patients with HIV/AIDS in Khon Kaen, Thailand.

Kitajima T, Kobayashi Y, Chaipah W, Sato H, Chadbunchachai W, Thuennadee R.

AIDS. 2003 Nov 7;17(16):2375-81.

PMID:
14571190
6.

Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study.

Sendi PP, Bucher HC, Harr T, Craig BA, Schwietert M, Pfluger D, Gafni A, Battegay M.

AIDS. 1999 Jun 18;13(9):1115-22.

PMID:
10397543
7.

The National Access to Antiretroviral Program for PHA (NAPHA) in Thailand.

Chasombat S, Lertpiriyasuwat C, Thanprasertsuk S, Suebsaeng L, Lo YR.

Southeast Asian J Trop Med Public Health. 2006 Jul;37(4):704-15.

PMID:
17121296
8.

One world, one hope: the cost of providing antiretroviral therapy to all nations.

Hogg RS, Weber AE, Craib KJ, Anis AH, O'Shaughnessy MV, Schechter MT, Montaner JS.

AIDS. 1998 Nov 12;12(16):2203-9.

PMID:
9833862
9.

A survey of the syntheses of active pharmaceutical ingredients for antiretroviral drug combinations critical to access in emerging nations.

Pinheiro Edos S, Antunes OA, Fortunak JM.

Antiviral Res. 2008 Sep;79(3):143-65. doi: 10.1016/j.antiviral.2008.05.001. Epub 2008 Jun 2. Review.

PMID:
18571246
10.

Cost effectiveness analysis of routine use of genotypic antiretroviral resistance testing after failure of antiretroviral treatment for HIV.

Corzillius M, Mühlberger N, Sroczynski G, Jaeger H, Wasem J, Siebert U.

Antivir Ther. 2004 Feb;9(1):27-36.

PMID:
15040534
11.

Treatment outcome and cost-effectiveness of different highly active antiretroviral therapy regimens in the UK (1996-2002).

Beck EJ, Mandalia S, Youle M, Brettle R, Fisher M, Gompels M, Kinghorn G, McCarron B, Pozniak A, Tang A, Walsh J, Williams I, Gazzard B.

Int J STD AIDS. 2008 May;19(5):297-304. doi: 10.1258/ijsa.2007.007236.

PMID:
18482958
12.

Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness.

Desai K, Sansom SL, Ackers ML, Stewart SR, Hall HI, Hu DJ, Sanders R, Scotton CR, Soorapanth S, Boily MC, Garnett GP, McElroy PD.

AIDS. 2008 Sep 12;22(14):1829-39. doi: 10.1097/QAD.0b013e32830e00f5.

PMID:
18753932
13.

Assessing efficiency and costs of scaling up HIV treatment.

Cleary SM, McIntyre D, Boulle AM.

AIDS. 2008 Jul;22 Suppl 1:S35-42. doi: 10.1097/01.aids.0000327621.24232.71.

PMID:
18664951
14.

Recurrent costs of HIV/AIDS-related health services in Rwanda: implications for financing.

Quentin W, König HH, Schmidt JO, Kalk A.

Trop Med Int Health. 2008 Oct;13(10):1245-56. doi: 10.1111/j.1365-3156.2008.02142.x. Epub 2008 Aug 20.

15.

Sustaining access to antiretroviral therapy in the less-developed world: lessons from Brazil and Thailand.

Ford N, Wilson D, Costa Chaves G, Lotrowska M, Kijtiwatchakul K.

AIDS. 2007 Jul;21 Suppl 4:S21-9. Review.

PMID:
17620749
16.

Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program.

Mauskopf JA, Tolson JM, Simpson KN, Pham SV, Albright J.

J Acquir Immune Defic Syndr. 2000 Apr 1;23(4):302-13.

PMID:
10836752
17.

The economic burden of HIV in the United States in the era of highly active antiretroviral therapy: evidence of continuing racial and ethnic differences.

Hutchinson AB, Farnham PG, Dean HD, Ekwueme DU, del Rio C, Kamimoto L, Kellerman SE.

J Acquir Immune Defic Syndr. 2006 Dec 1;43(4):451-7.

PMID:
16980906
18.

Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.

Freedberg KA, Kumarasamy N, Losina E, Cecelia AJ, Scott CA, Divi N, Flanigan TP, Lu Z, Weinstein MC, Wang B, Ganesh AK, Bender MA, Mayer KH, Walensky RP.

AIDS. 2007 Jul;21 Suppl 4:S117-28.

19.
20.

Antiretroviral therapy and HIV prevention in India: modeling costs and consequences of policy options.

Over M, Marseille E, Sudhakar K, Gold J, Gupta I, Indrayan A, Hira S, Nagelkerke N, Rao AS, Heywood P.

Sex Transm Dis. 2006 Oct;33(10 Suppl):S145-52.

PMID:
17003679

Supplemental Content

Support Center